Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-07-2017 | Letter to the Editor (by invitation)

Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

Authors: Bobak Bahrami, Thomas Hong, Andrew Chang

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2017

Excerpt

We acknowledge Drs. Călugăru for their interest in our recent publication “Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema” (DME) [1]. …

Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-017-3624-y

Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806CrossRef

Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022CrossRefPubMed

Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359CrossRefPubMedPubMedCentral

Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247–2254CrossRefPubMed

Ahmadieh H, Ramezani A, Shoeibi N et al (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 246:483–489

Bahrami B, Zhu M, Hong T, Chang A (2016) Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 59:1594–1608CrossRefPubMed

Title: Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
Authors: Bobak Bahrami
Thomas Hong
Andrew Chang
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3670-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2017

Macular morphology in former preterm and full-term infants aged 4 to 10 years

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data

Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients

Descemet membrane endothelial keratoplasty (DMEK) early stage graft failure in eyes with preexisting glaucoma

Non-invasive measurements of the dynamic changes in the ciliary muscle, crystalline lens morphology, and anterior chamber during accommodation with a high-resolution OCT

Erratum to: High-frequency aflibercept injections in persistent neovascular age-related macular degeneration